Fibrin thrombi form at sites of injury, where leukocytes release a variety of oxidants. To determine whether oxidants might affect proteins of the fibrinolytic system, we examined the effects of various oxidants on plasmin. Plasmin was not inhibited by micromolar concentrations of hypochlorous acid, chloramine T, or H,Oz. Neither Fe nor Cu affected plasmin alone or in the presence of H,Oz. However, incubation of plasmin with 5 pmol/L Cu(l or II) in the presence of the reducing agent ascorbic acid resulted in a loss of its hydrolytic activity towards proteins as well as towards small synthetic substrates. The addition of EDTA, but not mannitol, prevented its inactivation. Inactivation was prevented by the addition of catalase and accelerated by hydrogen peroxide. Preincubation of plasmin with the competitive inhibitor a-N-acetyl-L-lysine methyl ester prevented inactivation by Cu(ll) and ascorbate. These results together suggest site-specific oxidation of plasmin's active site. Treatment of the plasminogen activators tissue plasminogen activator and two-chain urokinase-type plasmin-T IS BECOMING increasingly recognized that fibrin clot I formation may be altered by exogenous substances, some of which may enter the blood as a direct consequence of cell injury.'-' However, little is known about the influence of substances released from injured or inflammatory cells on the fibrinolytic system. We have recently found that actin, which is released into the extracellular space after tissue injury,6 can have effects on the generation' or activity of plasmin.' Because the extracellular release of oxidants is a well-recognized consequence of tissue injury: we were interested in determining whether they might affect the function of proteins of the fibrinolytic system. We report here that, although plasmin is relatively resistant to inactivation by most oxidants tested, it can be inactivated by Cu(I1) and ascorbate. The combination of these two agents also inactivated all other serine proteases tested as well as two serine protease zymogens. These results suggest a common mechanism of site-specific oxidation of the enzymes' active site.
ogen activator, as well as trypsin, neutrophil elastase, and thrombin with Cu(ll) and ascorbate resulted in a loss of their amidolytic and proteolytic activity, indicating the general susceptibility of serine proteases to this type of oxidation. Oxidation of the zymogens Glu-plasminogen and single-chain urokinase-type plasminogen activator by Cu(ll) and ascorbate resulted in the failure of these molecules to generate active enzymes when treated with plasminogen activators or plasmin, respectively. The active site His residue may be the target of oxidative inactivation, as evidenced by the partial protection afforded plasmin by the addition of Zn(ll), histidine, orthe platinum derivative, platinum(11)(2,2:6',2"-terpyridine) chloride. Because platelets contain micromolar concentrations of Cu and leukocytes are rich in ascorbate, Cu-dependent site-specific oxidation might play a role in modulating proteolytic events and the life span of thrombi formed at sites of tissue injury. 0 1993 by The American Society of Hematology.
N-t-BOC-Val-Pro-Arg 7-amido-4-methylcoumarin, and trypsin. Platinum(II)(2,2':6',2"-terpyridine) chloride dihydrate ([Pt(trpy)-C1]+) and a-N-acetyl-L-lysine methyl ester (NALME) were obtained from Aldrich Chemical Co (Milwaukee, WI). S2251 ( H -~v a lLeu-Lys-pnitroanilide dihydrochloride), S2288 (H-D-Ile-Pro-Argp-nitroanilide dihydrochloride), S-2484 (Pyroglu-Pro-Val-pnitroanilide), and S-2444 (Pyroglu-Gly-Arg-p-nitroanilide), and human plasmin were obtained from KabiVitrum (Franklin, OH). S-2484 was dissolved in dimethylsulfoxide. Single-chain tissueplasminogen activator (t-PA) was from American Diagnostica (Greenwich, CT) and two chain urokinase-type plasminogen activator (tcu-PA) (Abbokinase) from Abbot Laboratories (North Chicago, IL). Recombinant single-chain high molecular weight u-PA prepared by Farmitalia (a generous gift of D r Ralph Pannell, New England Deaconess Hospital, Boston, MA) was treated with a fourfold molar excess of L-glutamyl-glycyl-L-arginine chloromethyl ketone and passed over a column of Sephadex G-25 before use.
Protein preparation. Plasmin was prepared and stored in 50% glycerol. t-PA was diluted in 10 mmol/L Tris, 150 mmol/L NaCI, pH 7.4, Tris-buffered saline (TBS) with 0.1% Tween 80. tcu-PA used in oxidation experiments was dialyzed against phosphate-buffered saline (PBS). Actin was prepared by the method of Pardee and Spudich." Glu-plasminogen was prepared by affinity chromatography on lysine-Sepharose in the presence of aprotinin." It was treated with 5 mmol/L EDTA before its final dialysis against TBS. Fibrinogen was prepared from citrated human plasma." Human sputum (neutrophil) elastase was obtained from Elastin Products Co, Inc (Owensville, MO). Trypsin was dialyzed against TBS after incubation with 5 mmol/L EDTA for 1 hour at room temperature.
Enzyme activity assays. Assays were performed at 37°C in wells of polystyrene microtiter plates (1 .O X 0.6 cm) that had been pretreated with 0.05% Tween-20 in PBS for 1 hour and then allowed to air-dry. Liberation of pnitroaniline at 37°C from synthetic substrates by the appropriate enzyme in 100 pL reaction mixtures of PBS was determined in a Thermomax microplate reader (Molecular Devices, Menlo Park, CA). For coupled reactions, the velocity of the reaction was determined by plotting the initial rate of change of the optical density at 405 nm against time quar red.'^ Thrombin was assayed in TBS with N-t-BOC-Val-Pro-Arg 7-amido-4-methylcoumarin using a Perkin-Elmer (Norwalk, Cr') spectrofluorometer (380 nm excitation and 460 nm emission). Thrombin's activity was also assessed by monitoring its ability to promote the development of clot turbidity at 340 nm after its addition to citrated plasma.
Electrophoretic analysis of enzymatic activity. Twenty-microliter reaction mixtures containing the proteins of interest were boiled in Laemmli's gel sample buffer14 and subjected to electrophoresis on 5% to 15% sodium dodecyl sulfate (SDS)-polyacrylamide gels under reducing or nonreducing conditions, as indicated in the text.
RESULTS
Plasmin was exposed to various oxidants for 30 minutes at 22°C and then assayed for residual amidolytic activity using S-225 1. As shown in Table 1 , plasmin's enzymatic activity was not affected by exposure to doses of chloramine T (< 1 mmol/L) that are likely to be generated physiologically, H,O, (5 presence of H,O, (1 mmol/L). However, addition of 1 mmol/L ascorbate to solutions containing plasmin and either Cu(I1) or Cu(1) resulted in a near total loss of plasmin's amidolytic activity (Fig 1) . Proteolysis of fibrinogen by plasmin treated with 5 pmol/L Cu(I1) and 1 mmol/L ascorbate was also inhibited, as assessed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (data not shown). The dose dependency of Cu(I1) and ascorbate is shown in Fig 2. Neither ascorbate nor Cu(I1) alone affected plasmin even when incubated for periods of 4 hours (data not shown). EDTA (5 mmol/L) protected plasmin from oxidation by Cu(I1) and ascorbate. Although the hydroxyl radical scavenger mannitol (50 mmol/L) did not inhibit plasmin's inactivation, the addition of catalase (0.2 U) inhibited inactivation by Cu(I1) and ascorbate ( Fig 3A) . In addition, added reagent H,O, accelerated inactivation of plasmin by Cu( 11) and ascorbate in a time-and dose-dependent manner (Fig 3B and C) . Together, these results suggest that inactivation was due to oxidation of plasmin. To determine whether the plasmin's active site was the primary target of the oxidant, plasmin was incubated with 5 mmol/L NALME, a small (239 daltons) competitive inhibitor of plasminI5 that blocks its amidolytic activity, before the addition of Cu(I1) and ascorbate. After 30 minutes, the mixture was diluted 10-fold, which allowed the NALME to dissociate from the enzyme's active site. As shown in Fig 4 , preincubation of plasmin with NALME prevented its inactivation by Cu(I1) and ascorbate. Oxidized plasmin also lost its ability to cleave 4-methylumbelliferyl p-guanidinobenzoate (MUGB) in a time-dependent fashion that paralleled the loss of amidolytic activity (data not shown). Oxidized plasmin was also unable to cleave two proteins substrates, fibrinogen (data not shown) and single-chain u-PA (scu-PA) (Fig 5) . Taken together, these findings suggest site-specific oxidationI6 of plasmin's active site.
To determine whether the zymogen was also sensitive to oxidation, Glu-plasminogen was incubated with Cu(I1) and ascorbate for 30 minutes, at which time EDTA was added to terminate the reaction. Conversion of Glu-plasminogen to plasmin was accomplished by the addition of various plasminogen activators (tcu-PA, streptokinase, or t-PA). As shown in Fig 6, exposure of Glu-plasminogen to Cu(I1) and ascorbate prevented the generation of active plasmin after the addition of tcu-PA. Similar results were seen when streptokinase or t-PA was used to generate plasmin (data not shown). Electrophoretic analysis showed that oxidation of Glu-plasminogen did not prevent its cleavage by streptokinase or tcu-PA (Fig 7) . Neither Glu-plasminogen nor plasmin formed dimers after Cu(II)/ascorbate treatment when subjected to SDS-PAGE under nonreducing conditions (data not shown).
We exposed the plasminogen activators urokinase (u-PA) and t-PA to Cu(I1) and ascorbate to determine if they too could be inactivated by Cu(I1) and ascorbate. Exposure of single chain t-PA, tcu-PA, or xu-PA to Cu(I1) and ascorbate resulted in a loss of their ability to cleave both protein and tripeptide synthetic substrates, as shown in Fig 8. Enzymatic activity was retained when either Cu(I1) or ascorbate was omitted (data not shown). Preincubation of t-PA with iodoacetamide neither affected t-PA's enzymatic activity nor protected it from oxidation by Cu(I1) and ascorbate, indicating that its free cysteine residue (CYS'~)'~ was not responsible for its oxidative inactivation. Streptokinase, which shows considerable homology to serine proteases but lacks the histidine residue equivalent to His57 of bovine trypsin," was not affected by Cu(I1) and ascorbate (data not shown).
Susceptibility of thrombin, elastase, and trypsin to Cu(IIj and ascorbate-mediated oxidation. Three other serine proteases were treated with Cu(I1) and ascorbate. As shown in by a 15-minute exposure to Cu(I1) and ascorbate, supporting the hypothesis that the active-site His is modified by Cu(I1) and ascorbate. Partial protection of plasmin from Cu(I1) and ascorbate was also seen when Zn(1I) or free histidine were present during the oxidation period (Fig 1 l) , further supporting the hypothesis of site-specific oxidation of the enzyme's active-site histidine. However, additional studies are required to prove this hypothesis.
DISCUSSION
It is well recognized that thrombi develop at sites of inflammation, areas characterized by the influx of leukocytes and by the consequent release of proteases and oxidants.' A number of factors are recognized to alter the rate of lysis of clots, especially the age of the clot:3 which may reflect the extent of fibrin cross-linking by factor XII124 or infiltration by collagen-producing fibroblast^.^' It is also possible that the life span of thrombi that form at sites of inflammation could be affected by substances such as proteases and oxidants that are released by activated inflammatory cells in the vicinity of the clot.
Several prior studies of the effects of proteases and oxidants on fibrinolytic proteins have been conducted that suggest that such interactions could promote fibrinolysis. For example, elastase, released by human neutrophils during blood coagulation,z6 can proteolyze fibrinogen." It can also digest plasminogen, creating a species known as "mini-plasminogen" that is more easily converted to plasmin than native Glu-plasminogen and less readily inhibited by a,-antipla~min.~*.~' In vitro oxidation of a key inhibitor of the fibrinolytic system, plasminogen activator inhibitor-1 (PAIl), can result in its inactivati~n.~~." If this occurs in vivo, fibrinolysis would be promoted. Unaware of previous studies of the effects of oxidants on the proteases of the fibrinolytic system, we undertook the studies described above to determine whether oxidant exposure could alter the function of these proteins.
Oxidants or oxidant systems were screened for their inhibitory effect on plasmin's amidolytic activity. Most had no effect on plasmin. Although chloramine T inhibited plasmin, the high doses required deterred us from exploring its mechanism of action further. The inactivation of plasmin by Cu(I1) and ascorbate was accelerated by added H202 and inhibited by catalase. Therefore, inactivation of plasmin is likely because of the formation of hydroxyl radicals or the oxidizing agent Cu( The inactivation of plasmin mediated by Cu(I1) and ascorbate prompted us to investigate their effects on other proteins involved in the fibrinolytic system. All such proteins that we examined were inhibited by Cu(I1) and ascorbate, except for streptokinase. (Streptokinase is homologous to the protease domains of other serine proteases. It is not an active protease because the active-site His residue is replaced by Gly.'*) Although copper-mediated oxidation of fibroblast growth factor-1 has been described in the absence of ascorbate,34 we found that ascorbate was required for rapid plasmin inactivation, suggesting a metal-catalyzed ox- (which together generate oxidant species) to inactivate plasmin and the inability of mannitol to inhibit Cu(I1) and ascorbate-induced inactivation suggests that the damage is not caused simply by the exposure of the protein to a flux of hydroxyl radicals. The ability of the competitive inhibitor NALME to block inactivation induced by Cu(I1) and ascorbate indicates that the key modification occurs at plasmin's active site. These results are consistent with a reaction that occurs in the microenvironment of the bound copper, ie, by a site-specific Fenton reacti~n.'~~''*~~ To explain inactivation of three different serine proteases (plasmin, t-PA, and u-PA) by Cu(I1) and ascorbate, we postulated that the histidine in the active site of each enzyme was the target of the oxidation reaction. Evidence that a His residue is a key target of oxidation comes from the partial protection afforded plasmin exposed to Cu(I1) and ascorbate by (1) the platinum derivative, [Pt(trpy)Cl]+, which has previously been shownZZ to reversibly bind the active site His of two serine proteases; ( 2 ) the addition of the histidinebinding metal, Zn(I1); and (3) the presence of free histidine during oxidation. However, additional studies are required to definitively prove this point.
For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From As might be expected from the findings with the various plasminogen activators we studied, other serine proteases (thrombin, elastase, and trypsin) were also inhibited by Cu(I1) and ascorbate. However, the rates and [Cu(II)] dependency of inhibition were not the same for all proteases. These differences may be caused by a number of factors, including the rate of association of Cu(I1) with the enzyme, the stability of the copper-enzyme complex, the number of accessible histidine and cysteine residues that might compete with the active site histidine, and the molar ratio of Cu(I1) to the enzyme. If the ratio of Cu(I1) to the protein in question is the crucial determinant of its inactivation, low concentrations of Cu(I1) may be physiologically important if the protein concentration is low, and there may not be a simple threshold for inactivation. These studies incidentally point to a simple way of inactivating a variety of serine proteases without using protease inhibitors. Oxidative inactivation of serine proteases by Cu(I1) and ascorbate may prove to be useful in various preparative procedures or as a means of generating inactive serine proteases that might be used in various ways. For example, oxidized enzymes might be used for inhibitor or receptor binding studies or as competitive antagonists of the native proteins.
It is generally believed that there is no free copper in plasma because it is bound to ceruloplasmin (whose plasma concentration is about 3 ~m o l / L )~~ and albumin. However, under certain conditions, ceruloplasmin may be damaged and release its bound copper, which then becomes available to participate in other reactions. This has been shown to be the case when serum is stored at 4°C'"' or when ceruloplasmin is exposed to a superoxide-generating sy~tem,~' trypsin,42 or high concentrations of ascorbate.43 The demonstration of discordance between functional (ferroxidase activity) and immunologic measurements of serum ceruloplasmin in smokersa and healthy volunteers taking ascorbic acid4' indicates that modulation of ceruloplasmin's copper-binding capacity may occur in vivo as well. This may lead to significant free copper concentrations if ceruloplasmin is damaged in a confined space (such as in the interior of a thrombus), because each ceruloplasmin binds to 6 or 7 cupric ions.
Other sources of bioreactive copper may exist as well. For example, it has been shown that Cu,Zn superoxide dismutase may be injured by H202 so that it loses enzymatic activity and releases its This may be relevant for the experiments described here, because this enzyme is an important component of red blood cells and is being developed as a potential therapeutic agent. In addition, it has recently been shown that copper is released into the coronary vasculature after 35 minutes of myocardial ischemia in the rat. 48 Platelets may be another source of copper, because their intracellular copper concentration has been estimated to be 17 to 113 ~m o l / L ,~~ and lysis of platelets after clot formation may release copper directly into a thrombus. Similarly, although plasma ascorbate concentrations average 50 pmol/L, the concentrations in neutrophils ( 1.2 mmol/L), monocytes (3.8 mmol/L), and platelets (1.9 mmol/L) are high enough to provide a significant concentration of this reducing agent in the vicinity of a thrombus."
Thus, site-specific oxidation of fibrinolytic serine proteases may affect the life span of a thrombus in certain situations. Because plasmin also regulates the activation of enzymes (ie, collagenase)'' and growth factors (ie, transforming growth factor p)52,53 that are important in the events that follow tissue injury, factors [such as Cu(l1)-mediated oxidation] that influence its production and/or activity may influence a variety of biologic processes, in addition to clot lysis.
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